SCHEMBL5230371

SCHEMBL5230371

CCCCOC(=O)C1(Cc2ccccc2)CN(C(=O)OC(C)(C)C)CCC1=O

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 1/20 0.38
P2RX3 P56373 1/20 0.38
STS P08842 1/20 0.38
ACHE P22303 1/20 0.38
USP30 Q70CQ3 1/20 0.38
SCD5 Q86SK9 1/20 0.37
OPRD1 P41143 2/20 0.37
OPRK1 P41145 2/20 0.37
KEAP1 Q14145 1/20 0.37
NFE2L2 Q16236 1/20 0.37
KLK7 P49862 4/20 0.36
KLK5 Q9Y337 4/20 0.36
PRSS1 P07477 2/20 0.36
PRSS2 P07478 2/20 0.36
PRSS3 P35030 2/20 0.36
CKS1B P61024 1/20 0.36
SKP1 P63208 1/20 0.36
SKP2 Q13309 1/20 0.36
CYP11B2 P19099 1/20 0.36
JAK2 O60674 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4479936 0.91 LMNA (0.42) GPR119P2RX3STSACHEUSP30
SCHEMBL5230008 0.87 STS (0.43) GPR119P2RX3STSACHEUSP30
SCHEMBL5229997 0.87 STS (0.43) GPR119P2RX3STSACHEUSP30
SCHEMBL5230017 0.87 STS (0.43) GPR119P2RX3STSACHEUSP30
SCHEMBL5230373 0.83 GPR119 (0.41) GPR119P2RX3STSACHEUSP30
SCHEMBL5246764 0.81 CNR1 (0.39)
SCHEMBL5246761 0.81 CNR1 (0.39)
SCHEMBL5246757 0.81 CNR1 (0.39)
SCHEMBL16490799 0.80 MEN1 (0.47) GPR119ALDH1A1CYP3A4TDP1L3MBTL1
SCHEMBL6414267 0.78 CYP11B2 (0.36) GPR119P2RX3USP30SCD5CYP11B2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1001970-B1 DIPEPTIDE DERIVATIVES AS GROWTH HORMONE SECRETAGOGUES PFIZER (US) 2007-03-07 EP disclosed
US-6953791-B2 Dipeptide derivatives PFIZER, INC. (US) 2005-10-11 US disclosed
US-6951850-B2 Dipeptide derivatives PFIZER, INC. (US) 2005-10-04 US disclosed
US-6924280-B2 Dipeptide derivatives PFIZER INC. (US) 2005-08-02 US disclosed
US-RE38524-E1 Dipeptide derivatives as growth hormone secretagogues PFIZER INC. 2004-06-01 US disclosed
US-20040009984-A1 Increasing levels of endogenous growth hormone, especially treating osterporosis, aging frailty or congestive heart failure CARPINO PHILIP ALBERT (US) 2004-01-15 US disclosed
US-20040006063-A1 Dipeptide derivatives CARPINO PHILIP ALBERT (US) 2004-01-08 US disclosed
US-20030216399-A1 Dipeptide derivatives CARPINO PHILIP ALBERT (US) 2003-11-20 US disclosed
US-6525047-B2 Which are growth hormone secretogogues and increase the level of endogenous growth hormone; treating osteoporosis, congestive heart failure, frailty associated with aging, obesity; accelerating bone fracture repair PFIZER INC. 2003-02-25 US disclosed
US-6433171-B1 FOR OSTEOPOROSIS AND/OR FRAILTY, CONGESTIVE HEART FAILURE, FRAILTY ASSOCIATED WITH AGING, OBESITY; ACCELERATING BONE FRACTURE REPAIR, ATTENUATING PROTEIN CATABOLIC RESPONSE AFTER A MAJOR OPERATION, REDUCING CACHEXIA AND PROTEIN LOSS PFIZER INC. 2002-08-13 US disclosed
US-6432945-B1 Dipeptide derivatives PFIZER INC. 2002-08-13 US disclosed
US-6429313-B2 Dipeptide derivatives PFIZER INC. 2002-08-06 US disclosed
US-20020065284-A1 Dipeptide derivatives CARPINO PHILIP ALBERT (US) 2002-05-30 US disclosed
US-20020042415-A1 Dipeptide derivatives CARPINO PHILIP ALBERT (US) 2002-04-11 US disclosed
US-20020002165-A1 Dipeptide derivatives CARPINO PHILIP ALBERT (US) 2002-01-03 US disclosed
US-20010041703-A1 Dipeptide derivatives CARPINO PHILIP ALBERT (US) 2001-11-15 US disclosed
US-6251902-B1 Dipeptide derivatives as growth hormone secretagogues PFIZER INC. 2001-06-26 US disclosed
EP-1001970-A1 DIPEPTIDE DERIVATIVES AS GROWTH HORMONE SECRETAGOGUES PFIZER INC. (US) 2000-05-24 EP disclosed
WO-1998058947-A1 DIPEPTIDE DERIVATIVES AS GROWTH HORMONE SECRETAGOGUES PFIZER INC. (US) 1998-12-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040009984-A1 Increasing levels of endogenous growth hormone, especially treating osterporosis, aging frailty or congestive heart failure GHSR, GHRHR, GIPR GPR119 59/4885P2RX3 703/4885STS 1804/4885
US-20020042415-A1 Dipeptide derivatives GIPR, GHRHR, GHSR GPR119 53/4885P2RX3 326/4885STS 2381/4885
US-20010041703-A1 Dipeptide derivatives GIPR, GHRHR, GHSR GPR119 55/4885P2RX3 424/4885STS 2194/4885
US-20020002165-A1 Dipeptide derivatives GIPR, GHRHR, GHSR GPR119 53/4885P2RX3 326/4885STS 2381/4885
US-20040006063-A1 Dipeptide derivatives GIPR, GHRHR, GHSR GPR119 40/4885P2RX3 570/4885STS 2084/4885
US-20030216399-A1 Dipeptide derivatives GIPR, GHRHR, GHSR GPR119 53/4885P2RX3 326/4885STS 2381/4885
US-20020065284-A1 Dipeptide derivatives GIPR, GHRHR, GHSR GPR119 53/4885P2RX3 326/4885STS 2381/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.